A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism

John A. Watts, Michael A. Gellar, Mary Beth K Fulkerson, Jeffrey Kline

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pulmonary embolism (PE) increases pulmonary vascular resistance, causing right ventricular (RV) dysfunction, and poor clinical outcome. Present studies test if the soluble guanylate cyclase stimulator BAY 41-8543 reduces pulmonary vascular resistance and protects RV function. Experimental PE was induced in anesthetized, male Sprague-Dawley rats by infusing 25 μm polystyrene microspheres (1.95 million/100 g body wt, right jugular vein) producing moderate PE. Pulmonary artery vascular resistance, estimated as RVPSP/CO, increased 3-fold after 5 h of PE. Treatment with BAY 41-8543 (50 μg/kg, I.V.; given at the time of PE induction) normalized this index by reducing RVPSP and markedly increasing CO, via preservation of heart rate and stroke volume. Ex vivo RV heart function showed minimal changes at 5 h of PE, but decreased significantly after 18 h of PE, including peak systolic pressure (PSP, Control 39 ± 1 mmHg vs. 19 ± 3 PE), +d. P/d. t (1192 ± 93 mmHg/s vs. 444 ± 64) and -d. P/d. t (-576 ± 60 mmHg/s vs. -278 ± 40). BAY 41-8543 significantly improved all three indices of RV heart function (PSP 35 ± 3.5, +d. P/d. t 1129 ± 100, -d. P/d. t -568 ± 87). Experimental PE produced increased PVR and RV dysfunction, which were ameliorated by treatment with BAY 41-8543. Thus, there is vasodilator reserve in this model of experimental PE that can be exploited to reduce the stress upon the heart and preserve RV contractile function.

Original languageEnglish
Pages (from-to)205-211
Number of pages7
JournalPulmonary Pharmacology and Therapeutics
Volume26
Issue number2
DOIs
StatePublished - Apr 2013

Fingerprint

Right Ventricular Function
Guanylate Cyclase
Pulmonary Embolism
Carbon Monoxide
Pressure control
Vascular Resistance
Polystyrenes
Right Ventricular Dysfunction
Microspheres
Vasodilator Agents
Rats
Soluble Guanylyl Cyclase
BAY 41-8543
Cardiac Volume
Jugular Veins
Stroke Volume
Pulmonary Artery
Sprague Dawley Rats
Theoretical Models
Heart Rate

Keywords

  • BAY 41-8543
  • Pulmonary embolism
  • Pulmonary heart disease
  • Pulmonary vascular resistance
  • Right ventricle
  • Soluble guanylate cyclase stimulator

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)
  • Biochemistry, medical

Cite this

A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism. / Watts, John A.; Gellar, Michael A.; Fulkerson, Mary Beth K; Kline, Jeffrey.

In: Pulmonary Pharmacology and Therapeutics, Vol. 26, No. 2, 04.2013, p. 205-211.

Research output: Contribution to journalArticle

@article{9741c33560f64b999a2c896695ca8593,
title = "A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism",
abstract = "Pulmonary embolism (PE) increases pulmonary vascular resistance, causing right ventricular (RV) dysfunction, and poor clinical outcome. Present studies test if the soluble guanylate cyclase stimulator BAY 41-8543 reduces pulmonary vascular resistance and protects RV function. Experimental PE was induced in anesthetized, male Sprague-Dawley rats by infusing 25 μm polystyrene microspheres (1.95 million/100 g body wt, right jugular vein) producing moderate PE. Pulmonary artery vascular resistance, estimated as RVPSP/CO, increased 3-fold after 5 h of PE. Treatment with BAY 41-8543 (50 μg/kg, I.V.; given at the time of PE induction) normalized this index by reducing RVPSP and markedly increasing CO, via preservation of heart rate and stroke volume. Ex vivo RV heart function showed minimal changes at 5 h of PE, but decreased significantly after 18 h of PE, including peak systolic pressure (PSP, Control 39 ± 1 mmHg vs. 19 ± 3 PE), +d. P/d. t (1192 ± 93 mmHg/s vs. 444 ± 64) and -d. P/d. t (-576 ± 60 mmHg/s vs. -278 ± 40). BAY 41-8543 significantly improved all three indices of RV heart function (PSP 35 ± 3.5, +d. P/d. t 1129 ± 100, -d. P/d. t -568 ± 87). Experimental PE produced increased PVR and RV dysfunction, which were ameliorated by treatment with BAY 41-8543. Thus, there is vasodilator reserve in this model of experimental PE that can be exploited to reduce the stress upon the heart and preserve RV contractile function.",
keywords = "BAY 41-8543, Pulmonary embolism, Pulmonary heart disease, Pulmonary vascular resistance, Right ventricle, Soluble guanylate cyclase stimulator",
author = "Watts, {John A.} and Gellar, {Michael A.} and Fulkerson, {Mary Beth K} and Jeffrey Kline",
year = "2013",
month = "4",
doi = "10.1016/j.pupt.2012.10.009",
language = "English",
volume = "26",
pages = "205--211",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism

AU - Watts, John A.

AU - Gellar, Michael A.

AU - Fulkerson, Mary Beth K

AU - Kline, Jeffrey

PY - 2013/4

Y1 - 2013/4

N2 - Pulmonary embolism (PE) increases pulmonary vascular resistance, causing right ventricular (RV) dysfunction, and poor clinical outcome. Present studies test if the soluble guanylate cyclase stimulator BAY 41-8543 reduces pulmonary vascular resistance and protects RV function. Experimental PE was induced in anesthetized, male Sprague-Dawley rats by infusing 25 μm polystyrene microspheres (1.95 million/100 g body wt, right jugular vein) producing moderate PE. Pulmonary artery vascular resistance, estimated as RVPSP/CO, increased 3-fold after 5 h of PE. Treatment with BAY 41-8543 (50 μg/kg, I.V.; given at the time of PE induction) normalized this index by reducing RVPSP and markedly increasing CO, via preservation of heart rate and stroke volume. Ex vivo RV heart function showed minimal changes at 5 h of PE, but decreased significantly after 18 h of PE, including peak systolic pressure (PSP, Control 39 ± 1 mmHg vs. 19 ± 3 PE), +d. P/d. t (1192 ± 93 mmHg/s vs. 444 ± 64) and -d. P/d. t (-576 ± 60 mmHg/s vs. -278 ± 40). BAY 41-8543 significantly improved all three indices of RV heart function (PSP 35 ± 3.5, +d. P/d. t 1129 ± 100, -d. P/d. t -568 ± 87). Experimental PE produced increased PVR and RV dysfunction, which were ameliorated by treatment with BAY 41-8543. Thus, there is vasodilator reserve in this model of experimental PE that can be exploited to reduce the stress upon the heart and preserve RV contractile function.

AB - Pulmonary embolism (PE) increases pulmonary vascular resistance, causing right ventricular (RV) dysfunction, and poor clinical outcome. Present studies test if the soluble guanylate cyclase stimulator BAY 41-8543 reduces pulmonary vascular resistance and protects RV function. Experimental PE was induced in anesthetized, male Sprague-Dawley rats by infusing 25 μm polystyrene microspheres (1.95 million/100 g body wt, right jugular vein) producing moderate PE. Pulmonary artery vascular resistance, estimated as RVPSP/CO, increased 3-fold after 5 h of PE. Treatment with BAY 41-8543 (50 μg/kg, I.V.; given at the time of PE induction) normalized this index by reducing RVPSP and markedly increasing CO, via preservation of heart rate and stroke volume. Ex vivo RV heart function showed minimal changes at 5 h of PE, but decreased significantly after 18 h of PE, including peak systolic pressure (PSP, Control 39 ± 1 mmHg vs. 19 ± 3 PE), +d. P/d. t (1192 ± 93 mmHg/s vs. 444 ± 64) and -d. P/d. t (-576 ± 60 mmHg/s vs. -278 ± 40). BAY 41-8543 significantly improved all three indices of RV heart function (PSP 35 ± 3.5, +d. P/d. t 1129 ± 100, -d. P/d. t -568 ± 87). Experimental PE produced increased PVR and RV dysfunction, which were ameliorated by treatment with BAY 41-8543. Thus, there is vasodilator reserve in this model of experimental PE that can be exploited to reduce the stress upon the heart and preserve RV contractile function.

KW - BAY 41-8543

KW - Pulmonary embolism

KW - Pulmonary heart disease

KW - Pulmonary vascular resistance

KW - Right ventricle

KW - Soluble guanylate cyclase stimulator

UR - http://www.scopus.com/inward/record.url?scp=84874560853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874560853&partnerID=8YFLogxK

U2 - 10.1016/j.pupt.2012.10.009

DO - 10.1016/j.pupt.2012.10.009

M3 - Article

C2 - 23142020

AN - SCOPUS:84874560853

VL - 26

SP - 205

EP - 211

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 2

ER -